Drug Hepatitis At AINS

1. Fernández-Villar, A., Sopeña, B., Vázquez, R., Ulloa, F., Fluiters, E., Mosteiro, M., César, M.- V. & Piñeiro, L. (2003). Isoniazid Hepatotoxicity among Drug Users: The Role of Hepatitis C. Clinical Infectious Diseases. 36(3), 293-298. doi: 10.1086/345906.Open DOISearch in Google Scholar

2. Gronhagen-Riska, C., Hellstrom, P.E. & Froseth, B. (1978). Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis. 118(3), 461-466. doi: 10.1164/arrd.1978.118.3.461Open DOISearch in Google Scholar

3. Huang, Y.S., Chern, H.D., Su, W.J., Wu, J.C., Lai, S.L., Yang, S.Y., Chang, F.Y. & Lee, S.D. (2002). Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 35(4), 883-889. doi: 10.1053/jhep.2002.32102Open DOISearch in Google Scholar

4. Huang, Y.S., Chern, H.D., Su, W.J., Wu, J.C., Chang, S.C., Chiang, C.H., Chang, F.Y. & Lee, S.D. (2003). Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis druginduced hepatitis. Hepatology. 37(4), 924-930. doi: 10.1053/jhep.2003.50144Open DOISearch in Google Scholar

5. Steele, M.A., Burk, R.F. & DesPrez, R.M. (1991). Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 99(2), 465-471.10.1378/chest.99.2.4651824929Search in Google Scholar

6. Yew, W.W. & Leung, C.C. (2007). Antituberculosis Drugs anbd Hepatotoxicity. Hong Kong Medical Diary, 12(1), 7-9Search in Google Scholar

7. de Abajo, F.J., Montero, D., Madurga, M. & Garcia Rodriguez, L.A. (2004). Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 58(1), 71-80. doi: 10.1111/j.1365-2125.2004.02133.xOpen DOISearch in Google Scholar

8. Jobanputra, P., Amarasena, R., Maggs, F., Homer, D., Bowman, S., Rankin, E., Filer, A., Raza, K. & Jubb, R. (2008). Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord. 9, 48. doi: 10.1186/1471-2474-9-48Open DOISearch in Google Scholar

9. Emery, P., Breedveld, F.C., Lemmel, E.M., Kaltwasser, J.P., Dawes, P.T., Gomor, B., Van Den Bosch, F., Nordstrom, D., Bjorneboe, O., Dahl, R., Horslev-Petersen, K., Rodriguez De La Serna, A., Molloy, M., Tikly, M., Oed, C., Rosenburg, R. & Loew-Friedrich, I. (2000). A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 39(6), 655-665.10.1093/rheumatology/39.6.65510888712Search in Google Scholar

10. Matteson, E. & Cush, J.J. (2001). Reports of leflunomide hepatotoxicity in patients with rheumatoid arthritis. ACR HotlineSearch in Google Scholar

11. Cohen, S.B. & Iqbal, I. (2003). Leflunomide. Int J Clin Pract. 57(2), 115-120.10.1111/j.1742-1241.2003.tb10439.xSearch in Google Scholar

12. Strand, V., Cohen, S., Schiff, M., Weaver, A., Fleischmann, R., Cannon, G., Fox, R., Moreland, L., Olsen, N., Furst, D., Caldwell, J., Kaine, J., Sharp, J., Hurley, F. & Loew-Friedrich, I. (1999). Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 159(21), 2542-2550.10.1001/archinte.159.21.254210573044Search in Google Scholar